SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending due to its recent 1-for-10 reverse stock split, sparking heated debates within the investment community about its potential impact and the company's future prospects. The community is closely monitoring the stock's performance post-split and discussing the potential for future catalysts like cannabis rescheduling, while also expressing concerns about potential dilution and the CEO's leadership. Chatter surrounds a potential connection between a Trump advisor and cannabis rescheduling, adding another layer of speculation to the stock's movement.

Fly-E Group, Inc. is an electric vehicle company, which engages in designing, installing, and selling smart electric motorcycles, electric bikes, electric scooters, and related accessories under the brand Fly E-Bike. Its products include electric-scooter, e-bikes, parts, and accessories. The company was founded by Zhou Ou in 2018 and is headquartered in Flushing, NY.

Fly-E Group Inc.

Fly-E Group Inc

FLYE is trending due to a massive intraday price surge, with community members discussing potential short squeeze opportunities given the high short interest and low float. Some traders caution about the stock's volatility and past history, while others point to potential for further gains. Overall, the stock's unusual price action is fueling speculative interest.

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

Janux Therapeutics Inc

Janux Therapeutics ($JANX) is trending due to mixed reactions to recent Phase 1 data for its JANX007 prostate cancer treatment, with the stock plummeting in after-hours trading despite analysts' initial positive assessments. The community is debating the efficacy compared to existing treatments and the potential impact of patient selection on the results, while some view the selloff as an overreaction and a buying opportunity, anticipating future data readouts and a potential buyout.

Hippo Holdings, Inc. is a home protection company which provides a new standard of care and protection for homeowners. It harnesses real-time data, smart home technology, and a growing suite of home services to create an integrated home protection platform. It operates through following segments: Services, Insurance-as-a-Service, and Hippo Home Insurance Program. The Services segment earns fees and/or commission income without assuming underwriting risk or need for reinsurance. The Insurance-as-a-Service segment earns a portion of the premiums paid to it for the risk the company retains as well as generates investment income. The Hippo Home Insurance Program segment involves the Hippo-branded homeowners insurance business. The company was founded by Assaf Wand on January 10, 2015 and is headquartered in San Jose, CA.

Hippo Holdings Inc

Hippo Holdings is trending as traders discuss recent options activity and potential long-term value, despite some concerns about short-term volatility. Some see it as an undervalued player in the insurtech space, drawing comparisons to peers like $LMND and $ROOT, while others highlight insider buying and potential catalysts. Discussions also mention a possible shift towards profitability and potential acquisition target status.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as its community rallies around the revival of OG memes and a shared vision for web3 culture, showing strong conviction in its potential. The community is actively creating content, expanding across platforms, and emphasizing the value of consistent effort over short-term price action. With a focus on community building and a return to unfiltered expression, $RAGE is positioning itself as more than just a token, but a movement.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is trending after reporting strong earnings and revenue growth, driven by demand for its high-speed connectivity solutions in AI infrastructure. The community is discussing the company's potential for further gains, especially given its strategic partnerships with hyperscalers. However, some are wary of the stock's high valuation and potential for a pullback.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

MRNA is trending amidst buyout rumors and anticipation surrounding upcoming earnings, as well as an investor day later this month. Community chatter speculates on potential partnerships or a complete acquisition, with some highlighting the company's cash reserves and pipeline value. However, others express concerns about declining revenue, and potential stricter regulatory pathways.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending as investors discuss its potential rebound following news of AI integration and recent acquisitions, with community members weighing in on earnings expectations and future growth prospects. Despite some bearish sentiment and concerns about slowing growth, analysts suggest optimism due to strong IT spending trends, Agentforce adoption, and a potential reversal. Community members highlight key resistance levels and potential catalysts for upward movement.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is trending following positive earnings results, with discussions centering on strong cloud growth and operating leverage. Upgrades from analysts, including Piper Sandler's Overweight rating and target price adjustment, are fueling optimism. The community is actively discussing the potential for further gains and comparing MDB's performance to competitors like Oracle.

English version Introducing SWFTCoin (SWFTC) $SWFTC: Powering SWFT Blockchain and AI Services (SWFTGPT)  SwftCoin ($SWFTC) is the native utility token driving SWFT Blockchain's AI-powered ecosystem, SWFTGPT, and the first ever AI token featured on Coinbase. SWFTGPT is also the first domain-specific LLM for crypto.  SwftCoin key features include: 50% Reduced Transaction Fees: Lower costs on all transactions. AI Service Payments: Use $SWFTC to access SWFTGPT. Tools include expert market analysis,  predictions, and intelligent trading solutions.  Membership Benefits: Unlock premium features and AI agent services within SWFTGPT. AI-Powered Swaps: Enable precise, fast cross-chain transactions and analytics. SWFT Blockchain combines AI innovation with blockchain infrastructure, simplifying crypto trading while enhancing functionality through $SWFTC.   Chinese version $SWFTC：驱动 SWFT Blockchain 和 AI 服务（SWFTGPT） SwftCoin ($SWFTC) 是 SWFT Blockchain 的原生实用代币，为其 AI 驱动的生态系统 SWFTGPT 提供支持，同时也是 Coinbase 上首个 AI 代币。SWFTGPT 也是首个专注于加密领域的特定领域大型语言模型 (LLM)。 SwftCoin 的主要功能包括： 1、50% 交易费减免：降低所有交易成本。 2、AI 服务支付：使用 $SWFTC 访问 SWFTGPT 工具，包括专家市场分析、预测以及智能交易解决方案。 3、会员权益：解锁 SWFTGPT 的高级功能和 AI 代理服务。 4、AI 驱动的闪兑：实现精准快速的跨链交易和数据分析。 SWFT Blockchain 将 AI 创新与区块链基础设施结合，通过 $SWFTC 简化加密交易，并提升其功能性。

SwftCoin

SwftCoin is trending as the community rallies around the project, fueled by discussions about potential pumps and its fully diluted status. Some community members are focused on its potential for significant gains and the possibility of outperforming other trending cryptos. There's also discussion regarding the potential for future partnerships and listings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Hepion Pharmaceuticals Inc. drew heightened attention from retail traders on Monday after the company disclosed that the Nasdaq Hearings Panel had ordered its delisting, citing violations of continued listing requirements.&nbsp;Trading in the company's common stock is set to be suspended at the open on Tuesday, with shares expected to move to the OTC Markets under the same ticker, HEPA.Hepion Pharmaceuticals shares closed down 18.8% at $0.32 on Monday, sliding 45% to $0.17 in after-hours trading.Retail sentiment on Stocktwits turned 'bullish' on Monday amid a 5,100% surge in 24-hour message volume.One user highlighted optimism around Hepion's core asset, Rencofilstat, describing it as a potentially "revolutionary" drug class.&nbsp;Rencofilstat is a cyclophilin inhibitor aimed at treating chronic liver diseases like NASH and hepatocellular carcinoma (HCC).The user suggested that although trial results may not be released soon, the drug could eventually displace existing therapies once they have been fully monetized.&nbsp;They added that the move to OTC "could get interesting."<stembedurl>https://stocktwits.com/BADBOYROY/message/614371348</stembedurl>Another user hoped the stock would be tradable on Robinhood after moving to the OTC market, suggesting the transition could trigger a strong upward move.<stembedurl>https://stocktwits.com/stock_trafficking/message/614386549</stembedurl>The delisting followed Nasdaq's determination that Hepion had failed to maintain the minimum bid price of $1.00 and was in breach of Rule 5101, which allows delisting of companies identified as public shells.Hepion recently entered a license agreement with New Day Diagnostics LLC to distribute tests for celiac disease, respiratory multiplex (COVID-19, Influenza A/B, RSV), H. pylori, and hepatocellular carcinoma (HCC).&nbsp;These tests carry CE marks, making them eligible for sale in Europe.The company had previously paused and then wound down its ASCEND-NASH Phase 2b trial for Rencofilstat, after enrolling 151 patients out of a planned 336.&nbsp;Approximately 80 patients completed a full year of treatment.The stock has declined 98.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Hepion Pharma Stock Draws Bullish Retail Bets Despite Nasdaq Delisting Notice: 'Could Get Interesting'

Despite a sharp decline in stock price, retail traders are optimistic about the company's potential, citing its core asset Rencofilstat and speculating on a rebound following the OTC transition.

Equity

Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer

Hepion Pharmaceuticals announces merger with Pharma Two B Ltd., creating a combined company focused on Parkinson's disease treatment. The merger values Hepion at $58.5 million, and Pharma Two B plans...

Hepion Pharmaceuticals' Strategic Merger and Corporate Restructuring

An update from Hepion Pharmaceuticals (HEPA) is now available. Hepion Pharmaceuticals has entered into a merger agreement with Pharma Two B Ltd. an...

Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?

Updates on Hepion Pharmaceuticals' ASCEND-NASH Trial, now in wind-down phase. Explore insights into Phase 2b study progression and strategic alternatives.
read more...

Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of...

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug...

Hepion Pharmaceuticals to Present at NASH-TAG 2024

EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ( AI )-driven therapeutic...

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate, Rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Morristown, NJ.

Hepion Pharmaceuticals Inc

$CRWD

$CRM

$SNOW

$MDB

Which earnings report are you most looking forward to this week? 
 
Drop a comment for others.

HEPA
Hepion Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest HEPA News

HEPAHepion Pharmaceuticals Inc